Trulicity FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved September 18, 2014)
Brand name: Trulicity
Generic name: dulaglutide
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction
Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Development timeline for Trulicity
| Date | Article |
|---|---|
| Sep 3, 2020 | Approval FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes |
| Feb 21, 2020 | Approval Trulicity (dulaglutide) Approved to Reduce Cardiovascular Events in Adults With and Without Established Cardiovascular Disease |
| Sep 18, 2014 | Approval FDA Approves Trulicity (dulaglutide) for Type 2 Diabetes |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.